Payment overview · 2025
General Payments
$18,154.71
234 reported records · 32 companies
Healthcare provider profile · identity verified
Jeffrey N Feldman, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · UNION, NJ · NPI 1124081336
Verified facts
What the public records show
CMS Open Payments records show Jeffrey N Feldman, MD received $18,154.71 in general payments during 2025 across 234 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 46.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rayaldee, Rybelsus, Velphoro, Veltassa.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Auryxia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 782 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 487 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nexlizet by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Velphoro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 487 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 287 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 423 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Rayaldee by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $8,342.51 | 46.0% | 27 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $5,608.03 | 30.9% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $677.00 | 3.7% | 34 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $506.00 | 2.8% | 17 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $502.27 | 2.8% | 16 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $307.10 | 1.7% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $280.99 | 1.6% | 11 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $244.58 | 1.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.19 | 1.1% | 12 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $184.75 | 1.0% | 12 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $150.60 | 0.8% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $147.85 | 0.8% | 5 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $124.91 | 0.7% | 7 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.78 | 0.7% | 8 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $106.10 | 0.6% | 7 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $86.98 | 0.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.83 | 0.4% | 4 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $60.52 | 0.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $56.98 | 0.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.01 | 0.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.89 | 0.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.58 | 0.2% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $38.55 | 0.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.33 | 0.2% | 2 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $32.87 | 0.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.87 | 0.1% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $22.26 | 0.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.12 | 0.1% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $20.09 | 0.1% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.12 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.69 | 0.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.36 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,233.50 | 9 |
| Food and Beverage | $5,604.15 | 214 |
| Travel and Lodging | $1,225.63 | 7 |
| Education | $91.43 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $8,342.51 | 27 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $5,749.00 | 25 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $476.75 | 22 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $307.10 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $281.87 | 12 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $244.58 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $204.78 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $200.25 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $194.19 | 12 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $172.75 | 11 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Pharmaceuticals, Inc. | $150.60 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $147.85 | 5 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $124.91 | 7 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $106.10 | 7 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $86.98 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $76.91 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $65.23 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.33 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $49.89 | 3 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $48.81 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $41.58 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.67 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.33 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $33.05 | 3 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $4.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 55 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 210 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 487 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 782 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 287 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 423 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 173 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
210 | 52 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
76 | 21 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
782 | 196 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
487 | 134 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
487 | 134 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
287 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
62 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
423 | 93 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
173 | 26 |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
100 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Kerendia | Finerenone | 782 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 626 | 196 |
| Jardiance | Empagliflozin | 487 | 134 |
| Ozempic | Semaglutide | 423 | 93 |
| Carvedilol | Carvedilol | 344 | 97 |
| Nifedipine Er | Nifedipine | 290 | 78 |
| Mounjaro | Tirzepatide | 287 | 46 |
| Farxiga | Dapagliflozin Propanediol | 210 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 203 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 59 |
| Ezetimibe | Ezetimibe | 178 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 174 | 53 |
| Rayaldee | Calcifediol | 173 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 135 | 36 |
| Famotidine | Famotidine | 130 | 39 |
| Chlorthalidone | Chlorthalidone | 127 | 45 |
| Allopurinol | Allopurinol | 125 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 36 |
| Trulicity | Dulaglutide | 106 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 37 |
| Veltassa | Patiromer Calcium Sorbitex | 100 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 31 |
| Clonidine Hcl | Clonidine Hcl | 89 | 25 |
| Losartan Potassium | Losartan Potassium | 89 | 33 |
| Xarelto | Rivaroxaban | 89 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 36 |
| Lokelma | Sodium Zirconium Cyclosilicate | 76 | 21 |
| Spironolactone | Spironolactone | 75 | 30 |
| Furosemide | Furosemide | 74 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 19 |
| Metformin Hcl | Metformin Hcl | 68 | 24 |
| Vascepa | Icosapent Ethyl | 67 | 21 |
| Entresto | Sacubitril/Valsartan | 62 | 22 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 62 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 20 |
| Valsartan | Valsartan | 61 | 21 |
| Omeprazole | Omeprazole | 60 | 18 |
| Calcitriol | Calcitriol | 59 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 23 |
| Eliquis | Apixaban | 55 | 18 |
| Amiloride Hcl | Amiloride Hcl | 52 | 16 |
| Pregabalin | Pregabalin | 47 | 17 |
| Repatha Sureclick | Evolocumab | 47 | 14 |
| Gabapentin | Gabapentin | 46 | 19 |
| Lisinopril | Lisinopril | 45 | 15 |
| Telmisartan | Telmisartan | 45 | 13 |
| Amoxicillin | Amoxicillin | 41 | 30 |
| Bumetanide | Bumetanide | 40 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Lidocaine | Lidocaine | 38 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 36 | 17 |
| Torsemide | Torsemide | 36 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Simvastatin | Simvastatin | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Auryxia | Ferric Citrate | 26 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 25 | 13 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Edarbi | Azilsartan Medoxomil | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18,154.71 · 234 records | Bayer Healthcare Pharmaceuticals Inc. | ACTHAR, AREXVY, BENLYSTA, BEYFORTUS, ELIQUIS, EVKEEZA, FARXIGA, FREESTYLE LIBRE, FUROSCIX, Filspari, GVOKE HYPOPEN, IBSRELA, JARDIANCE, JYNARQUE, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NEXLETOL, OTEZLA, Omnipod, Ozempic, RAYALDEE, REPATHA, Rybelsus, SHINGRIX, Saxenda, TARPEYO, TAVNEOS, TWIIST, VELPHORO, VERQUVO, VOYXACT, Vafseo, Veltassa, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AKEBIA THERAPEUTICS INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error